ULURU Inc. reported a net loss of $1.7 million, or $0.02 per share, in the fourth quarter of 2009. This was a strong improvement from the net loss of $2.9 million, or $0.04 per share, in the same quarter of 2008.

Renaat Van den Hooff, the CEO of ULURU Inc., said, “During the fourth quarter we continued with our restructured business operation which has provided us with a reduced cost structure while allowing us to further our strategic goals.”

In the full year 2009, ULURU Inc. lost $9.2 million, or $0.14 per share, slightly better than the net loss of $9.8 million, or $0.15 per share, in 2008. Revenues fell to $668,000 in 2009, down from $733,000 in 2008.

ULURU Inc. is a specialty pharmaceutical company that focuses on two areas: wound management and oral care. For the treatment of wounds, the company offers Altrazeal, which is a powder dressing containing its Nanoflex technology.

In the Oral Care market, the company offers Aphthasol and OraDisc A for the treatment of mouth ulcers, as well as other products designed to treat mouth pain and whiten teeth.